{
  "id": "1528344c-d421-4a3c-a80c-2e20d3d3ac3b",
  "patient_id": "908b9209-245c-45cb-8558-ca4f2800962b",
  "encounter_id": "c7a22607-5c2b-4e6d-b39d-f8ac89fd05f8",
  "analysis_type": "Genetic Testing Recommendation",
  "input_text": "Patient: Jorge Thomas, DOB: 1979-12-30, Gender: Male\n\nChief Complaint: headache\n\nS: No medical history\n\nO: No physical exam documented.\n\nA: No assessment documented.\n\nP: No plan documented.\n\n--- IMAGING & SCANS ---\n- Chest Scan (3/24/2025): Chest scan\n\n--- IMAGING & SCANS ANALYSIS ---\n\n[Scan 1: Chest Scan (2025-03-24T23:06:13.575979)]\nFile: images.jpeg\nDescription: Chest scan\nAnalysis: Okay, let\u2019s analyze this chest CT scan. \n\n**Overall Impression:**\n\nThis CT scan demonstrates significant bilateral pulmonary involvement, primarily characterized by diffuse, patchy opacities. The findings suggest an inflammatory or infiltrative process affecting the lungs.\n\n**Detailed Findings:**\n\n1. **Lung Fields:**  The lungs appear quite dense, with a significant amount of shadowing present throughout both lung fields. This is the key finding.\n\n2. **Patchy Opacities:** The most prominent feature is the presence of numerous, scattered, patchy areas of increased density (opacities) within the lung parenchyma. These aren't sharply defined nodules or masses. They appear more as \u201ccloud-like\u201d or \u201cpatchy\u201d infiltrates.\n\n3. **Distribution:** The opacities are bilaterally distributed \u2013 meaning they are present in both lungs.  They seem to be more prominent in the lower lobes, but this isn\u2019t entirely consistent throughout.\n\n4. **Bronchovascular Markings:**  The bronchial and pulmonary vascular structures (bronchovascular markings) are somewhat obscured by the surrounding opacities, making it harder to fully assess their anatomy.\n\n5. **Mediastinum:** The mediastinum (the space between the lungs containing the heart, great vessels, etc.) appears unremarkable.  The heart size appears within normal limits on this single slice.\n\n6. **Pleura:** The pleural surfaces (the linings of the lungs) appear clear, with no evidence of pleural effusion (fluid accumulation) visible on this slice. \n\n7. **Hilar Areas:** The hilar areas (where the bronchi and blood vessels enter the lungs) appear normal.\n\n\n**Possible Diagnoses (Differential Considerations):**\n\nBased on these findings, several possibilities need to be considered. This is not a definitive diagnosis, but a list of potential causes:\n\n*   **Pneumonia:** This is a strong consideration given the diffuse, patchy opacities.  It could be bacterial, viral, or atypical pneumonia.\n*   **Acute Respiratory Distress Syndrome (ARDS):** The diffuse opacities could be indicative of ARDS, a severe form of lung injury often following a significant illness or injury.\n*   **Diffuse Interstitial Lung Disease (ILD):**  This is a broad category of diseases characterized by inflammation and scarring in the lung\u2019s interstitium. The patchy nature of the opacities is consistent with some forms of ILD.\n*   **Pulmonary Edema:**  Although less\n",
  "recommendation": "recommended",
  "reasoning": "The chest CT scan reveals significant bilateral pulmonary involvement with diffuse, patchy opacities, suggesting an inflammatory or infiltrative process.  The differential diagnosis includes pneumonia, ARDS, diffuse interstitial lung disease (ILD), and pulmonary edema. The literature highlights a strong association between various forms of ILD and genetic factors.  Familial pulmonary fibrosis (FPF) is specifically mentioned, where individuals may be diagnosed with idiopathic pulmonary fibrosis (IPF), other forms of IIP, or connective tissue disease-associated ILD.  Given the significant lung involvement shown in the scan and the lack of other information in the patient's history to suggest a more common cause (e.g., infection, recent injury), genetic testing to investigate potential underlying genetic causes of ILD is warranted.  The absence of a family history does not exclude a genetic etiology, as some genetic conditions have variable penetrance or may represent de novo mutations.  Further investigation is needed to determine the specific type of ILD and whether a genetic basis is involved.  The patient's age (45 years old) is also consistent with the typical onset of some genetic ILDs.",
  "confidence": "70%",
  "model_used": "Gemini-Pro",
  "retrieved_docs": [
    {
      "id": "pf_txt_1",
      "contents": " Individual interstitial lung diseases are associated with diferent radiographic patterns and features. Radiographic patterns of lung involvement in individuals with certain pathogenic variants may be atypical (see Table 1). \n2. Genetic Causes of Pulmonary Fibrosis \nSuggestive Features of a Genetic Cause of Pulmonary Fibrosis \nTe presence of a genetic cause of predisposition to pulmonary fbrosis can be suggested by family history or by clinical features of a known genetic cause of pulmonary fbrosis (see Table 1 and Table 2). \nFamily history. Familial pulmonary fbrosis (FPF) describes the occurrence of fbrotic interstitial lung disease (ILD) in at least two related family members. Te specifc ILD diagnosis may vary in afected individuals from the same family [Lee et al 2012, Newton et al 2016]. Individuals with FPF may be clinically diagnosed with any of the following disorders: \n\u2022 Idiopathic pulmonary fbrosis ( $[\\sim\\!50\\%$ of individuals with FPF) [Borie et al 2016, Newton et al 2016]   \n\u2022 Chronic hypersensitivity pneumonitis $[{\\sim}10\\%$ of individuals with FPF) [Okamoto et al 2013, Borie et al 2016, Newton et al 2016]   \n\u2022 Progressive pulmonary fbrosis [Newton et al 2016]   \n\u2022 Idiopathic interstitial pneumonia (IIP) (e.g., unclassifable IIP, nonspecifc interstitial pneumonia, pleuroparenchymal fbroelastosis, among others) [Reddy et al 2012, Borie et al 2016, Newton et al 2016, Nunes et al 2017]   \n\u2022 Connective tissue disease-associated ILD, including rheumatoid arthritis ILD and scleroderma ILD [Juge et al 2017]   \n\u2022 Drug-induced ILD [Borie et al 2016]   \n\u2022 Pulmonary fbrosis and adenocarcinoma of the lung   \n\u2022 Combined pulmonary fbrosis and emphysema [Nunes et al 2014, Stanley et al 2015, Stanley et al 2016] \nAdenocarcinoma of the lung.",
      "token_count": 457,
      "sentence_count": 20
    },
    {
      "id": "pf_txt_21",
      "contents": "King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fbrosis. N Engl J Med. 2014;370:2083-92. PubMed PMID: 24836312.   \nKropski JA, Mitchell DB, Markin C, Polosukhin VV, Choi L, Johnson JE, Lawson WE, Phillips JA 3rd, Cogan JD, Blackwell TS, Loyd JE. A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. Chest. 2014;146:e1-7. PubMed PMID: 24504062.   \nKropski JA, Young LR, Cogan JD, Mitchell DB, Lancaster LH, Worrell JA, Markin C, Liu N, Mason WR, Fingerlin TE, Schwartz DA, Lawson WE, Blackwell TS, Phillips JA 3rd, Loyd JE. Genetic evaluation and testing of patients and families with idiopathic pulmonary fbrosis. Am J Respir Crit Care Med. 2017;195:1423-8. PubMed PMID: 27786550.   \nLee HY, Seo JB, Steele MP, Schwarz MI, Brown KK, Loyd JE, Talbert JL, Schwartz DA, Lynch DA. Highresolution CT scan fndings in familial interstitial pneumonia do not conform to those of idiopathic interstitial pneumonia. Chest. 2012;142:1577-83. PubMed PMID: 23364926.   \nMaher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Pirfenidone in patients with unclassifable progressive fbrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med.",
      "token_count": 491,
      "sentence_count": 21
    },
    {
      "id": "nf1_txt_18",
      "contents": " Symptoms are usually nonspecifc and may include dyspnea on exertion, shortness of breath, chronic cough, or chest pain. Symptoms do not usually appear until the third or fourth decade of life, although characteristic signs may be found on imaging studies in children with NF1 [Spinnato et al 2019]. Chest CT is the method of choice for identifying NF1-associated difuse lung disease, which typically is characterized by upper-lobe cystic and bullous disease and basilar interstitial disease. NF1 pulmonary disease is ofen poorly responsive to available medical treatments. \nGrowth \nIndividuals with NF1 tend to be below average in height and above average in head circumference for age [Zessis et al 2018]. However, very few individuals with NF1 have height more than 3 SD below the mean or head circumference more than 4 SD above the mean. \nIn contrast, individuals with whole-gene NF1 deletions have overgrowth (especially in height) between ages two and six years [Ning et al 2016, Kehrer-Sawatzki et al 2020]. Te clinical features in some of these individuals resemble those of Weaver syndrome (see Genotype-Phenotype Correlations). \nPubertal development is usually normal, although decreased pubertal growth velocity occurs in both girls and boys [Zessis et al 2018]. However, delayed puberty is common [Virdis et al 2003], and precocious puberty and/or growth hormone excess may also occur in children with NF1, especially in those with tumors of the optic chiasm [Cambiaso et al 2017, Hannah-Shmouni & Stratakis 2019]. \nLife Expectancy \nTe median life expectancy of individuals with NF1 is at least eight years lower than in the general population [Evans et al 2011, Wilding et al 2012]. Even higher excess mortality has been identifed in females [Uusitalo et al 2015]. Malignancy (MPNST) and vasculopathy are the most important causes of early death in individuals with NF1 [Evans et al 2011, Masocco et al 2011, Uusitalo et al 2015]. \nQuality of Life \n",
      "token_count": 472,
      "sentence_count": 15
    },
    {
      "id": "sickle_txt_29",
      "contents": " A macrolide antibiotic should be added if pneumonia/ACS is a concern.   \nAdditional antibiotics should be added only for proven or suspected meningitis or other severe illness. \n\nNote: With the changing natural history of fever and sepsis in individuals with SCD in the US there is increasing evidence that empiric treatment with parenteral antibiotics without obtaining cultures may be appropriate for well-appearing, fully immunized children with fever $<\\!39\\,^{\\circ}\\mathrm{C};$ ; however, this work has not yet been replicated [Baskin et al 2013, Ellison et al 2015] nor has it become widely accepted practice. Tere are additional published clinical pathways that outline outpatient management [Ellison et al 2018, Erno et al 2022]. \nAcute chest syndrome (ACS). Te index of suspicion for ACS should be high when individuals with SCD have fever, chest pain, or signs or symptoms of respiratory compromise. Given the high mortality associated with ACS, an aggressive multimodal treatment strategy should be initiated [Miller 2011]: \n\u2022 Perform chest radiograph examination.   \n\u2022 Provide aggressive treatment with oxygen, analgesics, and antibiotics (including a macrolide).   \n\u2022 Incentive spirometry should be encouraged.   \n\u2022 Hypoxemia can progress to need for intubation and mechanical ventilatory support.   \n\u2022 Simple RBC transfusion may be required for those who are critically ill, have multilobar disease, or have progressive disease despite conservative therapy.   \n\u2022 Emergent RBC exchange should be considered in certain severe cases in which the hemoglobin is greater than $10\\,\\mathrm{g/dL}$ and/or the HbS is greater than $30\\%$ ; however, the quality of evidence in this area is still low [NHLBI 2014, Dolatkhah & Dastgiri 2020]. \nStroke. Any history of an acute neurologic symptom or event warrants emergent evaluation including a CBC with reticulocyte count and a noncontrast brain CT examination. Cerebral hemorrhage requires immediate neurosurgical consultation. An MRI/MRA to defne injury should be obtained as soon as available, but defnitiv e treatment with exchange transfusion should never be delayed for these results. \nTreatment for children with acute ischemic stroke includes the following: \n",
      "token_count": 491,
      "sentence_count": 18
    },
    {
      "id": "cgd_txt_19",
      "contents": "Other conditions associated with abnormal dihydrorhodamine (DHR) test results. Other conditions that may afect the ability of the neutrophil to generate the respiratory burst that is detected in the DHR assay include myeloperoxidase defciency (OMIM 254600) [Mauch et al 2007] and SAPHO (the syndrome of synovitis, acne, pustulosis, hyperostosis, and osteitis) [Daoussis et al 2019]. In these two conditions the DHR results are \nabnormal, but superoxide production levels and NBT staining are normal. In addition, neither of these syndromes has infection profles that overlap with CGD. \nRecently, acetominophen administration has been shown to afect the DHR assay and should be considered in the diferential of a low DHR response [Almutairi et al 2020]. \nManagement \nNo clinical practice guidelines for chronic granulomatous disease (CGD) have been published. \nEvaluations Following Initial Diagnosis \nTo establish the extent of disease and needs in an individual diagnosed with chronic granulomatous disease (CGD), the evaluations summarized in Table 5 (if not performed as part of the evaluation that led to the diagnosis) are recommended. \nTable 5. Recommended Evaluations Following Initial Diagnosis in Individuals with Chronic Granulomatous Disease (CGD) \nAffected Organs / Manifestations of CGD on Imaging \nLungs/pneumonia [Godoy et al 2008] \n\u2022 Chest x-ray. Consolidation, reticular nodular opacities, scarring   \n\u2022 CT \u26ac Consolidation, ground-glass opacity, tree-in-bud opacity, centrilobular or random nodules, septal thickening, air trapping, scarring \u26ac Empyema or abscess \u26ac Mediastinal or hilar adenopathy, honeycomb lung, pleural thickening in chronic cases \u26ac Contiguous spread to chest wall, associated osteomyelitis of ribs and vertebral bodies   \n\u2022 PET [G\u00fcng\u00f6r et al 2001]. Increased uptake at areas of consolidation \nLymph nodes / suppurative adenitis [Towbin & Chaves 2010] \nCT. Enhancing lymph node with central area of hypodensity and enhancing septations   \n",
      "token_count": 480,
      "sentence_count": 19
    },
    {
      "id": "prolidase-def_txt_9",
      "contents": " A few afecte d individuals have been reported with hemophagocytic lymphohistiocytosis / macrophage activation syndrome, which required emergent management (see Management) [Chidambaram et al 2021, Rossignol et al 2021]. \nImmunologic studies may reveal the following (see also Suggestive Findings): \n\u2022 Elevated levels of IgG, IgA, and IgM   \n\u2022 Hypocomplementemia   \n\u2022 Decreased neutrophil chemotaxis   \n\u2022 Increased serum IgE levels, ranging from $20,000\\;\\mathrm{IU/mL}$ to $77,600\\;\\mathrm{IU/mL}$   \n\u2022 Grimbacher scores for hyper IgE syndrome were 34 (possible) for one afected individual [Lopes et al 2002] and 41 (probable) in another [Hershkovitz et al 2006]. \nPulmonary Manifestations \nAsthma-like chronic reactive airway disease has been described in approximately $7\\%$ of afected individuals. \nOther forms of chronic pulmonary disease occasionally see \n\u2022 Bronchiectasis, chronic lipoid pneumonia, and a cystic fbrosis-like phenotype with elevated sweat chloride and transepithelial potential diference. One man developed severe progressive restrictive lung disease at age 45 years [Luder et al 2007].   \n\u2022 Progressive lung disease with chest CT fndings of mainly cystic lung lesions and ground glass opacity in a Druze woman age 24 years [Butbul Aviel et al 2012]. She experienced further deterioration in her pulmonary function and secondary pulmonary hypertension and became oxygen dependent.   \n\u2022 Pulmonary hypertension requiring supplemental oxygen in an Amish child age six years [Kelly et al 2010]   \n\u2022 Pulmonary fbrosis with pulmonary capillaritis and cystic lung changes in two individuals age fve years [Rayment et al 2019] and 22 years, respectively. Te latter individual required oxygen therapy by age 33 years [Cottin et al 2020]. \nAutoimmune Disorders and Systemic Lupus Erythematosus-Like Findings \nAbout one ffh of individuals with prolidase defciency develop an autoimmune disorder.",
      "token_count": 455,
      "sentence_count": 19
    },
    {
      "id": "higes_txt_8",
      "contents": "\u2022 Symptoms of esophageal dysmotility are present in more than $50\\%$ of individuals and manifest as gastrointestinal refux and dysphagia.   \n\u2022 Upper endoscopy frequently shows eosinophilic esophagitis.   \n\u2022 Diverticula can occur at a relatively young age and may be associated with bowel perforation [Stover et al 2010].   \n\u2022 Spontaneous intestinal perforations have also been described. Signifcant gastrointestinal bleeds can occur from aneurysms and Dieulafoy lesions (abnormally large artery in the lining of the gastrointestinal system). \nMajor Causes of Morbidity and Mortality \nSurvival is typically into adulthood, but a shortened life span was typical in the past. Most individuals are now living into or past the sixth decade. \n\u2022 Most deaths of individuals with STAT3-HIES are associated with gram-negative (Pseudomonas) or flamentous fungal pneumonias (most commonly Aspergillus) infecting damaged lung parenchyma (i.e., preexisting pneumatoceles, bronchiectasis) [Freeman et al 2007b]. Fungi may invade the pulmonary vasculature leading to massive hemoptysis, or may disseminate to multiple organs. \u2022 Myocardial infarction may be related to coronary artery aneurysms and subarachnoid hemorrhage may be related to intracranial aneurysms [Fathi et al 2011]. \u2022 Lymphomas occur at an increased frequency; treatment with standard chemotherapy has been successful. \nGenotype-Phenotype Correlations \nNo genotype-phenotype correlations for STAT3 missense pathogenic variants have been identifed. \nPenetrance \nIntrafamilial variability is minimal and penetrance appears to be complete. \nNomenclature \nDominant-negative pathogenic variants in STAT3 were identifed as the cause of autosomal dominant hyper IgE syndrome (AD-HIES) and \"Job syndrome\" in 2007. Since this time, other clinically overlapping dominant genetic disorders have been characterized and the term AD-HIES is no longer specifc to the dominant-negative STAT3 phenotype.",
      "token_count": 477,
      "sentence_count": 19
    },
    {
      "id": "pf_txt_24",
      "contents": "Reddy TL, Tominaga M, Hansell DM, von der Tusen J, Rassl D, Parfrey H, Guy S, Twentyman O, Rice A, Maher TM, Renzoni EA, Wells AU, Nicholson AG. Pleuroparenchymal fbroelastosis: a spectrum of histopathological and imaging phenotypes. Eur Respir J. 2012;40:377-85. PubMed PMID: 22441748.   \nRichards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-24. PubMed PMID: 25741868.   \nRicheldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, et al. Efcacy and safety of nintedanib in idiopathic pulmonary fbrosis. N Engl J Med. 2014;370:2071-82. PubMed PMID: 24836310.   \nSalisbury ML, Hewlett JC, Ding G, Markin CR, Douglas K, Mason W, Guttentag A, Phillips JA 3rd, Cogan JD, Reiss S, Mitchell DB, Wu P, Young LR, Lancaster LH, Loyd JE, Humphries SM, Lynch DA, Kropski JA, Blackwell TS. Development and progression of radiologic abnormalities in individuals at risk for familial interstitial lung disease. Am J Respir Crit Care Med. 2020;201:1230-9. PubMed PMID: 32011901.   \n",
      "token_count": 483,
      "sentence_count": 19
    },
    {
      "id": "pph_txt_2",
      "contents": "Te approach to the individual with suspected PAH has been carefully described by several international guidelines [Gali\u00e8 et al 2016]. Note: It is generally advised, when possible, to involve a specialty pulmonary hypertension referral center during the diagnostic work up. \nOnce symptoms or signs concerning for PAH are identifed on clinical exam, the following evaluations are recommended: \n\u2022 Electrocardiogram   \n\u2022 Transthoracic echocardiogram   \n\u2022 Laboratory work to include complete blood count, comprehensive metabolic panel, brain natriuretic peptide, antinuclear antibody, Rh factor, HIV testing, and coagulation studies Computed tomography of the chest and likely a ventilation/perfusion scan and pulmonary function studies \nUltimately, the diagnosis of PAH is formally made at the time of cardiac catheterization at rest, which is recommended for all individuals with suspected PAH. \n\u2022 Specifcally, cardiac catheterization is used to confrm the diagnosis of PAH by directly measuring pulmonary artery pressures and excluding other cardiac abnormalities. Challenge testing with vasodilators (i.e., inhaled nitric oxide) or fuid loading, or both, during catheterization is important to assess physiologic responses to guide appropriate therapy. \nDifferential Diagnosis of HPAH \nOther cardiopulmonary causes of PH are far more common than PAH. Importantly, causes of PH associated with related conditions need to be excluded before the diagnosis of PAH can be established. Other causes of PH include connective tissue diseases, cirrhosis, HIV infection, treatment with appetite suppressants, and the following acquired and hereditary disorders [Badesch et al 2010]: \n\u2022 Heart disease (WSPH Group 2). Most advanced cardiac conditions, including lef ventricular dysfunction, congenital heart disease, valvular disease, and cardiomyopathy, can cause PH. Heart diseases are detected by physical examination, electrocardiogram, echocardiography, and cardiac catheterization.   \n\u2022 Lung disease or hypoxia (WSPH Group 3). Te advanced stages of all lung diseases may cause PH. Most lung diseases that cause PH are identifed by detection of abnormal lung sounds on physical examination, pulmonary function testing, and/or high-resolution computed tomographic lung imaging.   \n",
      "token_count": 475,
      "sentence_count": 20
    },
    {
      "id": "sickle_txt_13",
      "contents": " ACS ofen develops in the setting of a vaso-occlusive episode or with other acute manifestations of \nSCD, frequently afer two to three days of severe vaso-occlusive pain. ACS can progress rapidly (over several hours to days) to requiring intubation and mechanical ventilatory support. A high index of suspicion is indicated; the presenting signs and symptoms of ACS can be highly variable, and afecte d individuals may initially have a normal physical examination [Morris et al 1999]. Multiple etiologies, o fen occurring simultaneously, can contribute to ACS (e.g., fat emboli from bone marrow infarcts, pneumonia, pulmonary infarction, pulmonary embolus, asthma) [Mekontso Dessap et al 2011, Klings & Steinberg 2022]. \nNeurologic complications in SCD include stroke, silent cerebral infarcts, cerebral hemorrhage, cerebral blood fow abnormalities including moyamoya disease, and cerebral microvascular disease. Up to $50\\%$ of individuals with SCD will manifest some degree of cerebrovascular disease by age 14 years [Bernaudin et al 2011]. \n\u2022 Ischemic strokes, most ofen seen in children and older adults, are among the most catastrophic manifestations of SCD. Common presenting signs and symptoms include hemiparesis, monoparesis, seizures, aphasia or dysphasia, cranial nerve palsies, and mental status changes. Prior to routine screening with transcranial Doppler (TCD), overt strokes occurred in as many as $11\\%$ of children with SCD in the United States, with the peak occurrence between ages two and nine years. Without therapy, strokes recur in $50\\%-70\\%$ of afected individuals within three years afer the frst event. Transfusion therapy instituted afer an initial stroke has signifcantly reduced this risk [Serjeant 2013]. Narrowing of cerebral vessels is a risk factor for stroke, and elevated fow velocity on TCD identifes most children at high risk [Adams et al 1998], allowing intervention prior to the development of stroke [DeBaun & Kirkham 2016].",
      "token_count": 477,
      "sentence_count": 14
    },
    {
      "id": "ddon_txt_7",
      "contents": "Slowly progressive decline in visual acuity leads to legal blindness around age 30 to 40 years [Tranebjaerg et al 1995, Ponjavic et al 1996, Tranebjaerg et al 2000a, Tranebjaerg et al 2000b, Tranebjaerg et al 2001]. \nOther characteristics \n\u2022 Males with DDON syndrome have normal fertility. \n\u2022 Frequent occurrence of hip fractures in afected males appears to be associated with poor neuromuscular coordination and increased risk for stumbling rather than an abnormality in calcium metabolism or intrinsic bone abnormalities [Tranebjaerg et al 1995].   \n\u2022 Cardiomyopathy does not occur.   \n\u2022 Decrease in respiratory capacity does not occur, except for that related to aspiration pneumonia. \nHeterozygotes \nOlder females from the original family described by Tranebjaerg et al [1995] possibly had mild involvement. Recently, females ascertained through families with classically afected males have been shown to have mild hearing impairment and focal dystonia (e.g., \"writer's cramp\") [Swerdlow & Wooten 2001, Swerdlow et al 2004]. While skewed X-chromosome inactivation may contribute to this phenomenon [Orstavik et al 1996, Plenge et al 1999], X-chromosome inactivation studies were not reported in the families with the most severely involved heterozygous females [Swerdlow & Wooten 2001, Swerdlow et al 2004]. \nn reported [Swerdlow & Wooten 2001, Klempir et al 2010, Ha \nNeuroimaging (CT, MRI, or PET scan) shows general brain atrophy in the majority of males from age 40 years or, in some cases, earlier [Tranebjaerg et al 2001]. \nMore sophisticated neuroimaging studies such as PET/MRI reveal hypometabolic areas, predominantly over the right striatum and parietal cortex, and marked atrophy of the occipital lobes [Hayes et al 1998, Swerdlow & Wooten 2001, Ujike et al 2001, Binder et al 2003]. \nNeurophysiologic investigations show cochlear dysfunction. \n",
      "token_count": 465,
      "sentence_count": 15
    },
    {
      "id": "alpha1-a_txt_9",
      "contents": " For example, in the National Heart, Lung, and Blood Institute Registry, of 1,129 participants with severe defcienc y of AAT, $84\\%$ described dyspnea, $76\\%$ wheezed with an upper respiratory tract infection, and $50\\%$ reported cough and phlegm [McElvaney et al 1997, Eden et al 2003]. Of note, the prevalence of AATD in persons with asthma does not difer from that found in the general population [Wencker et al 2002, Miravitlles et al 2003]. \nMost individuals $(\\sim\\!95\\%)$ with severe AATD have evidence of bronchiectasis on chest CT, with $27\\%$ demonstrating clinical symptoms of bronchiectasis [Parr et al 2007]. \n\u2022 Chest CT shows loss of lung parenchyma and hyperlucency. In contrast to the usual pattern observed in centriacinar emphysema (emphysematous changes more pronounced in the lung apices than bases), the pattern observed in two thirds of individuals with AATD is that of more pronounced emphysematous changes in the bases than apices [Parr et al 2004]. \u2022 Lung function tests show decreased expiratory airfow, increased lung volumes, and decreased difusin g capacity. Approximately $60\\%$ of individuals with AATD-associated emphysema demonstrate a component of reversible airfow obstruction, defned as a $200{\\-}{\\bmod{L}}$ and $12\\%$ increase in the post-bronchodilator $\\mathrm{FEV}_{1}$ and/or FVC. \n\nChildhood-onset lung disease. Although reported, emphysema in children with AATD is extremely rare and may result from the coexistence of other unidentifed genetic factors afecting the lung [Cox & Talamo 1979]. \nStudies that followed newborns with severe AAT defciency through age 32 years showed that most adults did not smoke and lacked physiologic and CT evidence of emphysema [Mostafavi et al 2018]. Longer-term followup studies are not currently available.",
      "token_count": 484,
      "sentence_count": 12
    },
    {
      "id": "krabbe_txt_9",
      "contents": "Children with disease onset between ages 24 months and four years can initially manifest loss of milestones and vision (including rapid loss of vision) or gait changes and seizures. \nAlthough disease progression is variable, children who develop symptoms between ages nine months and four years may have rapid worsening of symptoms shortly afer presentation. In most instances death occurs approximately four to six years afer onset [M Escolar, personal communication]. \nInitial manifestations in children older than age six years may be behavioral difculties (attention-defcit/ hyperactivity disorder and mood disorders) followed by motor difculty. Tey ofen decline rapidly soon  afer disease onset [Fiumara et al 2011]. \nSome individuals with onset in adolescence and adulthood present with loss of manual dexterity, burning paresthesias in their extremities, and weakness without intellectual deterioration; others become bedridden and continue to deteriorate mentally and physically [Kolodny et al 1991, Satoh et al 1997, Jardim et al 1999, Wenger 2003]. Presenting manifestations in adult-onset disease can also include unilateral upper-limb weakness and lower-limb hypoesthesia [Debs et al 2013]. Disease progression is generally slower in the adult-onset disease than in adolescent-onset disease. \nTe adult-onset group includes individuals in whom the diagnosis was frst made in adulthood (because the subtle symptoms present earlier in life did not prompt biochemical testing) as well as individuals considered completely normal until manifestations began afer age 20 years [Kolodny et al 1991, Satoh et al 1997, Wenger 2003]. An example of the former is a woman reported by Kolodny et al [1991] (case 15) who had been \"shaky\" in childhood, walked slowly with a stif and wide-based gait, and had progressive, generalized neurologic deterioration afer age 40 years. She died of pneumonia at age 73 years. An example of the latter is a woman who developed slowly progressive spastic paraparesis at age 38 years. Demyelination identifed on MRI was confne d to the corticospinal tract [Satoh et al 1997]. \n",
      "token_count": 463,
      "sentence_count": 13
    },
    {
      "id": "hmerf_txt_5",
      "contents": "Muscle MRI can be useful earlier in the disease course and is thought to be highly specifc, with distinctive early involvement of the semitendinosus muscle [Birchall et al 2005]. Later in the disease course, numerous muscles become afected and this pattern may be nonspecifc [Pfefer et al 2012]. \nMuscle pathology can demonstrate fndings that are considered to be specifc to this disorder, but because of the patchy nature of abnormalities in myofbrillar myopathies, these fndings are not present in all afecte d individuals [Selcen 2011]. \nTe specifc fndings described with this disorder include the presence of \"cheetah-print\" aggregates [Pfefer et al 2014a] and \"necklace\" inclusions [Uruha et al 2015]. \nOtherwise, features of myofbrillar myopathy such as eosinophilic cytoplasmic inclusions on hematoxylin and eosin staining and cytoplasmic bodies on electron microscopy may be present, but are not specifc for HMERF. Other nonspecifc myopathic fndings may be present. \nRespiratory Findings \nA distinctive feature of this condition is the early diaphragmatic weakness that ofen occurs while individuals are still ambulant, which is typical of only a few other rare diseases (see Diferential Diagnosis) or may be atypically present in other rare myopathies [Pfefer & Povitz 2016]. Exertional dyspnea and/or orthopnea are the typical presenting symptoms, and pulmonary function testing demonstrates restrictive impairment. Patients develop progressive reduction in vital capacity and forced expiratory volumes, and ofen progress to require nocturnal noninvasive ventilatory support [Pfefer et al 2012]. \nProgression \nMost individuals require walking aids within a few years of onset, most commonly ankle-foot orthoses. Some will progress to wheelchair dependence and require nocturnal noninvasive ventilatory support about ten years afer onset. \nWeakness of respiratory muscles also progresses with time. Afected individuals become increasingly vulnerable to pulmonary infections as respiratory function deteriorates. \n",
      "token_count": 462,
      "sentence_count": 14
    },
    {
      "id": "cgd_txt_42",
      "contents": "Godoy MC, Vos PM, Cooperberg PL, Lydell CP, Phillips P, M\u00fcller NL. Chest radiographic and CT manifestations of chronic granulomatous disease in adults. AJR Am J Roentgenol. 2008;191:1570\u20135. PubMed PMID: 18941103.   \nGono T, Yazaki M, Agematsu K, Matsuda M, Yasui K, Yamaura M, Hidaka F, Mizukami T, Nunoi H, Kubota T, Ikeda S. Adult onset X-linked chronic granulomatous disease in a woman patient caused by a de novo mutation in paternal-origin CYBB gene and skewed inactivation of normal maternal X chromosome. Intern Med. 2008;47:1053\u20136. PubMed PMID: 18520120.   \nGreenberg DE, Ding L, Zelazny AM, Stock F, Wong A, Anderson VL, Miller G, Kleiner DE, Tenorio AR, Brinster L, Dorward DW, Murray PR, Holland SM. A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. PLoS Pathog. 2006;2:e28. PubMed PMID: 16617373.   \nGreenberg DE, Goldberg JB, Stock F, Murray PR, Holland SM, Lipuma JJ. Recurrent Burkholderia infection in patients with chronic granulomatous disease: 11-year experience at a large referral center. Clin Infect Dis. 2009;48:1577\u20139. PubMed PMID: 19400745.   \nGreenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002;110:685\u201392. PubMed PMID: 12417875.   \nG\u00fcng\u00f6r T, Engel-Bicik I, Eich G, Villi UV, Nadal D, Hossle JP, Seger RA, Steinert HC. Diagnostic and therapeutic impact of whole body positron emission tomography using fuorine-18-fuoro-2-deoxy-Dglucose in children with chronic granulomatous disease. Arch Dis Child. 2001;85:341\u20135.",
      "token_count": 477,
      "sentence_count": 27
    },
    {
      "id": "alpha1-a_txt_8",
      "contents": ", $\\mathrm{PI^{*}Z Z)}$ have low serum AAT levels, placing them at increased risk for chronic obstructive pulmonary disease (COPD) (see Table 4). Individuals with alleles associated with intrahepatic inclusions (e.g., Z, Mmalton, Siiyama) are also at increased risk of developing liver disease. \nUnder-recognition of AATD ofen causes a long delay between frst symptoms and initial diagnosis of AATD (i.e., 5-7 years) and many individuals report seeing multiple physicians before the diagnosis is frst established. Diagnostic delay is associated with worsened clinical status at the time of initial diagnosis [Tejwani et al 2019]. \nTo date, approximately 5,000-10,000 individuals in the United States have been identifed with a pathogenic variant in SERPINA1 [American Toracic Society & European Respiratory Society 2003, Strnad et al 2020].  Te following description of the phenotypic features associated with this condition is based on these reports. \nLung Disease \nAdult-onset lung disease. Chronic obstructive pulmonary disease (COPD), specifcally emphysema and/or chronic bronchitis, is the most common clinical manifestation of AATD. Bronchiectasis is also associated with AATD. \nIn adults, smoking is the major factor in accelerating the development of COPD. Although the natural history of AATD varies, depending in part on what has brought the individual to medical attention (e.g., lung symptoms, liver symptoms, asymptomatic relative of an afected individual), the onset of respiratory disease in smokers with AATD is characteristically between ages 40 and 50 years [Tanash et al 2008]. Nonsmokers may have a normal life span, but can also develop lung and/or liver disease. \nIndividuals with severe AATD may manifest the usual signs and symptoms of obstructive lung disease, asthma, and chronic bronchitis (e.g., dyspnea, cough, wheezing, and sputum production) [McElvaney et al 1997].",
      "token_count": 461,
      "sentence_count": 18
    },
    {
      "id": "bhd_txt_11",
      "contents": " Multiple familial trichoepithelioma 1 is caused by pathogenic variants in CYLD; the genetic basis of multiple familial trichoepithelioma 2 is unknown (OMIM 612099). \n3. Most syndromes with an increased risk of renal cancer are associated with renal pathology that is distinct from that seen in individuals with BHDS-related renal tumors [Linehan et al 2005]. \nOther conditions to consider in the diferential diagnosis of BHDS \n\u2022 Pulmonary Langerhans cell histiocytosis is a rare acquired smoking-related interstitial lung condition characterized by abnormal proliferation of histiocytes that predisposes for pneumothorax. Lung x-rays ofen show micronodular and interstitial infltrates and individuals may develop pulmonary fbrosis and pulmonary hypertension. Tese symptoms are not typical for BHDS [Mendez et al 2004]. \n\u2022 Sporadic pulmonary lymphangioleiomyomatosis (LAM) is a condition characterized by multiple lung cysts and pneumothorax. Te sporadic form ( $85\\%$ of all individuals with LAM) is more common than LAM associated with tuberous sclerosis $(15\\%)$ . Somatic TSC1/TSC2 pathogenic variants have been identifed in some individuals, but the disorder is ofen of unknown etiology. It afects mainly woman of childbearing age. Spontaneous pneumothorax is ofen the frst manifestation. Features atypical for BHDS are an even distribution of cysts throughout the lung, dyspnea on exertion, hemoptysis, and chylothorax. \nManagement \nEvaluations Following Initial Diagnosis \nTo establish the extent of disease and needs in an individual diagnosed with Birt-Hogg-Dub\u00e9 syndrome (BHDS), the evaluations summarized in Table 4 (if not performed as part of the evaluation that led to the diagnosis) are recommended. \nded Evaluations Following Initial Diagnosis in Individuals with Birt-Hog \nTreatment of Manifestations \nFibrofolliculomas.",
      "token_count": 449,
      "sentence_count": 17
    },
    {
      "id": "eds-pd_txt_8",
      "contents": " Tis risk appears lower than in people with vascular EDS, in which $72\\%$ of individuals with one or more vascular complications have been reported [Frank et al 2015]. \nOrgan rupture. Multiple organ ruptures were reported in two of 148 afected individuals $(1.4\\%)$ . One individual, age 67 years, had a history of recurrent pneumothoraces, an intestinal perforation, and an inguinal hernia [Kapferer-Seebacher et al 2016]. Te other individual, age 57 years, had a rupture of the lung and diaphragm [Kapferer-Seebacher et al 2019]. \nOther \nAcrogeric changes of the hands and feet seen in pEDS [George et al 2016] are reminiscent of those observed in vascular EDS. \nHoarse high-pitched voice has been reported in two individuals with pEDS to date [George et al 2016, Kapferer-Seebacher et al 2019]. Voice abnormalities have occasionally been described in other types of EDS; it has been hypothesized that they may be due to defects in the collagen of the vocal ligament [George et al 2016]. \nBrain white matter abnormalities. All adults investigated by brain MRI reported to date had brain white matter abnormalities [Spranger et al 1996, Kapferer-Seebacher et al 2019]. \nTe MRI pattern was suggestive of an underlying small-vessel disease that is progressive with age. As observed in other leukoencephalopathies related to microangiopathies, the extent of the white matter changes was disproportionate to the paucity of neurologic features. Medical history revealed recurrent headaches or depression in single cases. Neurologic examination was unremarkable in all individuals except one who had mild cognitive decline, ataxia, and a history of one seizure. \nClinical manifestations in children. All but one child with pEDS reported to date were identifed because of a positive family history. Generalized lack of attached gingiva is the only clinical fnding that is consistently present in afected children younger than age ten years [Kapferer-Seebacher et al 2021]. \n",
      "token_count": 471,
      "sentence_count": 17
    },
    {
      "id": "myotonia-c_txt_19",
      "contents": "Author History \n",
      "token_count": 2,
      "sentence_count": 1
    },
    {
      "id": "iiae3_txt_2",
      "contents": "Infection-induced acute encephalopathy 3 (IIAE3) refers to the susceptibility to recurrent acute necrotizing encephalopathy (ANE) caused by mutation of RANBP2 that is inherited in an autosomal dominant manner. Acute necrotizing encephalopathy refers to the specifc neurologic presentation in which bilateral symmetric thalamic, midbrain, and/or hindbrain lesions occur within days following the onset of an acute viral illness [Mizuguchi et al 1995]. \nSuggestive Findings \nInfection-induced acute encephalopathy 3 (IIAE3) is suspected in individuals with the following: \n\u2022 No preceding developmental or neurologic defects [Mizuguchi et al 1995, Neilson et al 2003]   \n\u2022 Signs at onset that can be attributed to a viral trigger, such as fever, cough, rhinorrhea, vomiting, diarrhea and malaise \u26ac Viruses known to precipitate ANE include infuenza A, infuenza B, parainfuenza II, human herpesvirus 6, coxsackie virus, and enteroviruses [Neilson 2010]. \u26ac Te only bacterium known to precipitate ANE is Mycoplasma pneumonia [Ashtekar et al 2003].   \n\u2022 Onset of ANE beginning within 12 hours to three or four days of the frst awareness of viral symptoms. Te most common sign of ANE is lethargy that progresses to coma and seizures $(50\\%)$ . \n\u2022 At the time of hospital admission, brain MRI demonstrating: \n\u26ac $\\mathrm{T}_{2^{-}}$ and FLAIR-weighted hyperintensities in the bilateral thalami, midbrain, cerebellum, pons, and brain stem [Mizuguchi et al 1995, Neilson et al 2003];   \n\u26ac Additional involved regions including the limbic system (e.g., the amygdala, mammillary bodies) and lateral regions such as the claustra and external capsules [Neilson 2010]; Note: Te presence of lesions in these areas should prompt consideration of IIAE3, even in the absence of recurrence or family history [Neilson 2010].   \n\u26ac Less commonly, involvement of the basal ganglia [Neilson 2010].",
      "token_count": 492,
      "sentence_count": 14
    },
    {
      "id": "nkx2-1-dis_txt_8",
      "contents": " Subtle abnormalities in presynaptic dopamine transporter function utilizing positron emission tomography (PET) imaging have also been reported in two afected individuals [Konishi et al 2013]. \nNeuropathology. Autopsies of two individuals with NKX2-1-related disorders did not identify gross or microscopic abnormalities of the brain, but showed reduced number of striatal and neocortical interneurons consistent with a defect in neuronal migration and supporting the theory that these disorders are due to abnormalities in brain development rather than neurodegeneration [Kleiner-Fisman et al 2003]. \nPulmonary Manifestations \nPulmonary dysfunction is the second most common manifestation of NKX2-1-related disorders. In a metaanalysis of 29 published reports of NKX2-1-related disorders, up to $49\\%$ (61/124) of afected individuals had pulmonary manifestations of varying severity [Gras et al 2012]. Clinical presentation and course vary among afected individuals. \n\u2022 Respiratory distress syndrome (RDS) with or without pulmonary hypertension is most common in the neonatal period.   \n\u2022 Neuroendocrine cell hyperplasia, a distinct form of childhood interstitial lung disease (ILD), can be present in infancy; it typically improves with age [Young et al 2013]. ILD can occur between the ages of four months to seven years.   \n\u2022 Pulmonary fbrosis can occur in older individuals [Hamvas et al 2013]. \nTe highest risk for respiratory distress is in the neonatal period. Afected infants ofen require mechanical ventilation [Carr\u00e9 et al 2009]. Although usually not fatal, NKX2-1-related disorders have resulted in death from respiratory failure in three infants in the immediate postnatal period to date [Maquet et al 2009, Kleinlein et al 2011, Gillett et al 2013]. However, in most infants, respiratory function typically improves over time [Young et al 2013]. \nAs a result of pulmonary involvement, individuals with NKX2-1-related disorders are at increased risk for recurrent pulmonary infections and chronic interstitial lung disease [Carr\u00e9 et al 2009, Inzelberg et al 2011, Peca et al 2011].",
      "token_count": 466,
      "sentence_count": 16
    },
    {
      "id": "ada2-def_txt_14",
      "contents": "\u2022 Complete physical examination with emphasis on: \u26ac Blood pressure and other vital signs, as systemic hypertension and/or fever are common. \u26ac Skin examination for evidence of livedo reticularis/racemosa, nodules, and Raynaud phenomenon. Severe involvement can include digital infarcts/gangrene or skin ulcerations. \u26ac Assessment for lymphadenopathy and hepatosplenomegaly. \u26ac Neurologic examination for evidence of prior or recent strokes. \n\u2022 Ophthalmologic examination for vision loss, diplopia, retinal infarcts, optic nerve damage, uveitis, ptosis, strabismus, and nystagmus Electrocardiogram (ECG) for manifestations of portal hypertension, including prolonged QT interval \nLaboratory assessment \u26ac Complete blood count (CBC) with diferential to detect anemia, lymphopenia, neutropenia, and/or thrombocytopenia \u26ac Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) as elevated levels may correlate with disease activity \u26ac Kidney and liver function tests \u26ac Quantitative serum immunoglobulins \u26ac PT/PTT to assess the risk of stroke in a patient who has not had a stroke OR to assess the risk of subsequent strokes in those who have had a stroke \u26ac Autoantibodies including antinuclear antibodies and lupus anticoagulant. Low titers are reported in $10\\%$ of patients, whereas high titers suggest other autoimmune diseases, such as systemic lupus erythematous. \u26ac Antineutrophilic cytoplasmic antibodies (ANCA) are usually absent; their presence suggests ANCA-related vasculitis. \u26ac Lymphocyte phenotyping. Failure to develop memory B-cells, a common fnding, is evidence of a Bcell maturation defect that warrants further evaluation of the immune system (quantitative serum immunoglobulins, antibody response to vaccines, and history of severe and/or multiple infections). Failure to develop memory T-cells may be seen but is uncommon. \u26ac Antibody response to vaccines. Inadequate response suggests immune defciency. \n\u2022 Imaging assessment \n",
      "token_count": 472,
      "sentence_count": 15
    },
    {
      "id": "ada_txt_13",
      "contents": "Noninfectious lung disease, frequently associated with alveolar proteinosis, appears to occur more frequently in individuals with ADA-SCID than with other genetic causes of SCID [Booth et al 2012, Grunebaum et al 2012, Kuo et al 2020]. Pulmonary dysfunction has also been identifed using the efort-independent technique of impulse oscillometry [Komarow et al 2015]. Historically, about $30\\%$ of individuals with ADA defciency have developed chronic pulmonary complications including asthma, bronchiectasis, bronchiolitis obliterans, and interstitial lung disease [Kuo et al 2020, Grunebaum et al 2023]. \nPhysical fndings include growth failure and the absence of lymphoid tissues (tonsils, lymph nodes). Tymu s shadow is absent on radiographs. Te characteristic radiographic changes of anterior rib cupping, scapular spurring, and other skeletal abnormalities that are present at the time of diagnosis in about $50\\%$ of individuals with ADA-SCID [Verhagen et al 2020] may resolve afer treatment [Manson et al 2013]. \nIn addition to marked depletion of T, B, and NK cell lymphocytes, some individuals with ADA-SCID may show reduced neutrophil counts and bone marrow abnormalities including myeloid dysplasia and hypocellularity [Sokolic et al 2011, Kim et al 2019, Kuo et al 2020]. \nOther system involvement. Abnormal liver function tests and various neurologic or behavioral abnormalities, which may be clinically signifcant, can occur both before and afer immunodefciency is diagnosed [Bollinger et al 1996, Tanaka et al 1996, Rogers et al 2001, Albuquerque & Gaspar 2004, Nofech-Mozes et al 2007, Sauer et al 2017, Kuo et al 2020, Grunebaum et al 2023]. Te prevalence of non-lymphoid system involvement is variable and may be infuenced by infections, antibiotic therapy, and other risk factors. Te efect of more rapid diagnosis and earlier institution of specifc treatment (i.e., enzyme replacement therapy, hematopoietic stem cell transplantation, or gene therapy) has yet to be determined. \n\u2022 Liver.",
      "token_count": 496,
      "sentence_count": 12
    },
    {
      "id": "tuberous-sclerosis_txt_32",
      "contents": "Gupta N, Finlay GA, Kotlof RM, Strange C, Wilson KC, Young LR, Taveira-DaSilva AM, Johnson SR, Cottin V, Sahn SA, Ryu JH, Seyama K, Inoue Y, Downey GP, Han MK, Colby TV, Wikenheiser-Brokamp KA, Meyer CA, Smith K, Moss J, McCormack FX; ATS Assembly on Clinical Problems. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. an ofcial American Toracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2017;196:1337\u201348. PubMed PMID: 29140122. \n",
      "token_count": 176,
      "sentence_count": 6
    },
    {
      "id": "leukodys-ov_txt_1",
      "contents": "Clinical characteristics \n",
      "token_count": 2,
      "sentence_count": 1
    },
    {
      "id": "dkc_txt_11",
      "contents": " Pulmonary fbrosis is manifest as bibasilar reticular abnormalities, ground glass opacities, or difuse nodular lesions on high-resolution computed tomography and abnormal pulmonary function studies that include evidence of restriction (reduced vital capacity with an increase in FEV1/FVC ratio) and/or impaired gas exchange (increased $\\mathrm{P}_{(\\mathrm{A}-\\mathrm{a})}\\mathrm{O}_{2}$ with rest or exercise or decreased difusion capacity of the lung for carbon monoxide). \nPulmonary arteriovenous malformations have recently been reported in individuals with DC/TBD [Khincha et al 2017]. Tey may be present in individuals with hypoxia in the absence of pulmonary fbrosis and can be diagnosed by bubble echocardiography. \nSevere Forms of DC/TBD \nHoyeraal Hreidarsson syndrome, a very severe form of DC/TBD, presents in early childhood [Walne & Dokal 2008]. In addition to features of DC/TBD, cerebellar hypoplasia is required to establish the diagnosis (see Figure 2). The findings in the original cases included cerebellar hypoplasia, developmental delay, immunodeficiency, IUGR, and bone marrow failure, as well as the DC/TBD diagnostic triad [Hoyeraal et al 1970]. \nRevesz syndrome has many of the features of DC/TBD and presents in early childhood [Revesz et al 1992]. In addition to features of DC/TBD, bilateral exudative retinopathy is required to establish the diagnosis.  Te individuals in the original reports had intracranial calcifcations, IUGR, bone marrow failure, and sparse, fn e hair in addition to nail dystrophy and oral leukoplakia. \nCoats plus syndrome may include DC/TBD-related mucocutaneous changes, such as dystrophic nails and sparse or graying hair [Anderson et al 2012, Polvi et al 2012].",
      "token_count": 449,
      "sentence_count": 11
    },
    {
      "id": "isselbacher-et-al-2022-2022-acc-aha-guideline-for-the-diagnosis-and-management-of-aortic-disease-a-report-of-the_txt_122",
      "contents": "BP should be measured in both arms and both lower extremities, to exclude a BP differential resulting from an AAS. One should auscultate for the murmurs of aortic stenosis, perhaps indicating an underlying BAV, and AR, which commonly accompanies type A aortic dissection. \n7.2. AAS: Diagnostic Evaluation (Imaging, Laboratory Testing) \nSynopsis \nA plain chest x-ray is neither sufficiently sensitive nor specific for AAS to be used to be diagnostic, but certain radiographic findings (Table 23) may raise suspicion of aortic dissection or suggest an alternate diagnosis for the patient\u2019s symptoms, in particular when there is previous radiography that shows the changes to be new in the interval.1,2,7 Fortunately, CT, TEE, and MRI are all highly accurate for the diagnosis of AAS.3 Aortography is rarely used given its invasive nature and significantly lower sensitivity than the other imaging modalities.8 Acute aortic dissection risk scoring systems (eg, aortic dissection detection risk score [AAD-RS] or aorta simplified score [AORTAs]) can aid in the diagnostic evaluation of patients presenting with AAS (Table 24 and Table 25)5,9-12 but have not been uniformly adopted.4 No biomarkers are considered diagnostic, although in patients with a low previous probability of AAS a nonelevated D-dimer (<500 ng/mL) makes the diagnosis unlikely. Consequently, integrating a low aortic dissection risk score and a low D-dimer may be a useful strategy to exclude the diagnosis of AAS.13 \nRecommendation-Specific Supportive Text \n1. Although the sensitivity and specify of CT, MRI, and TEE are all high,3 CT has become the preferred modality for evaluating most patients with suspected AAS. CT is widely available at all hours in the emergency department and is quick to perform. Not only does it diagnose the underlying AAS, it also shows the full extent of the dissection and, in some cases, the entry tear site. CT can detect the presence and mechanism of aortic branch vessel involvement as well as vessel patency, signs of malperfusion, pericardial effusion and hemopericardium, periaortic or mediastinal hematoma, and pleural effusion.",
      "token_count": 499,
      "sentence_count": 14
    },
    {
      "id": "gsd2_txt_14",
      "contents": " Echocardiographic assessment for dilatation of the ascending thoracic aorta has been recommended [El-Gharbawy et al 2011]. \nPulmonary \n\u2022 IOPD. Most infants have varying degrees of respiratory insufciency. Respiratory status should be established with regard to cough, presence of wheezing or labored breathing, and/or feeding difcult ies. Diaphragmatic weakness caused by excessive glycogen deposits results in mild to moderate reduction of vital capacity; however, objective assessment of pulmonary functions in infants is difcult at best. Most infants display respiratory difculty with feeds or sleep disturbance [Kravitz et al 2005]. \u2022 LOPD. Afected individuals should be evaluated for cough, wheezing, dyspnea, energy level, exercise tolerance, and fatigability. Formal pulmonary function tests show pulmonary insufciency. An attempt to assess ventilatory capacity in the supine position can detect early ventilatory insufciency. Pulse oximetry, respiratory rate, and venous bicarbonate and/or $\\mathrm{PCO}_{2}$ should be obtained to assess for alveolar hypoventilation [van der Beek et al 2011, Cupler et al 2012]. \nNutrition/feeding \n\u2022 IOPD. Afected individuals should be evaluated for possible feeding difculties (e.g., facial hypotonia, macroglossia, tongue weakness, and/or poor oromotor skills) [Jones et al 2010, van Gelder et al 2012]. Assessment of growth (i.e., height, weight, head circumference), energy intake, and feeding (including video swallow study) is appropriate. All infants should be evaluated for gastroesophageal refux disease.   \n\u2022 LOPD. Assessment of nutritional status as baseline is recommended. Assessment of swallowing difcult y by video swallow study may identify barriers to adequate nutrition and risk for aspiration. Gastrointestinal symptoms similar to those reported in individuals with irritable bowel syndrome may be underreported in this population and may undermine quality of life. \nAudiologic \u2013 IOPD \n\u2022 Baseline hearing evaluation including tympanometry is appropriate. See Genetic Hearing Loss Overview for a discussion of age-related methods of hearing evaluation.   \n",
      "token_count": 486,
      "sentence_count": 21
    },
    {
      "id": "alstrom_txt_12",
      "contents": " Teir risk of advanced NAFLD and cirrhosis is disproportionately increased for their age, BMI, and duration of diabetes [Gathercole et al 2016]. Plasma concentration of liver enzymes is ofen elevated starting in early childhood. Hepatomegaly is common. In some afected individuals liver disease progresses to cirrhosis and hepatic failure in the second to third decade. Portal hypertension associated with splenomegaly, esophageal varices, ascites, and hepatic encephalopathy may occur. \nLiver biopsies and postmortem examination have revealed varying degrees of steatohepatitis, hepatic fbrosi s, cirrhosis, chronic nonspecifc active hepatitis with lymphocytic infltration, and patchy necrosis [Quiros-Tejeira et al 2001, Marshall et al 2005]. Early stages of steatohepatitis can remit and relapse with signifcan t improvements in exercise tolerance, insulin resistance, and blood sugar [Paisey et al 2014]. \nGastrointestinal disease. General gastrointestinal disturbances such as epigastric pain and gastroesophageal refux disease are common. \nPulmonary involvement ranges in severity from frequent upper and lower respiratory infections to pulmonary fbrosis and pulmonary hypertension. Recurrent upper and lower respiratory infections are common at all ages. Evaluation of pulmonary function is problematic because individuals with Alstr\u00f6m syndrome have difcult y with deep inspiration / forced expiration. Most frequently there is restrictive lung disease due to kyphoscoliosis, sometimes in combination with pulmonary fbrosis, which has been confrmed in postmortem tissue. Tis may progress (with the added efects of cardiomyopathy) to pulmonary hypertension. Te resulting susceptibility to severe hypoxia postoperatively or during episodes of pneumonia has been reported [Khoo et al 2009, Florentzson et al 2010]. \nA study of the burden of otosinopulmonary disease in 38 individuals with Alstr\u00f6m syndrome revealed that recurrent otitis media was ubiquitous $(92\\%)$ , with $50\\%$ requiring pressure-equalization tube placement [Boerwinkle et al 2017].",
      "token_count": 490,
      "sentence_count": 16
    },
    {
      "id": "npab_txt_12",
      "contents": " Many untreated individuals with NPD-B have elevated transaminases and some have histologic abnormalities ranging from hepatic fbrosis to frank cirrhosis [Turberg et al 2012]. In rare instances, liver failure has required liver transplantation [McGovern et al 2013]. However, ERT has been shown to improve hepatomegaly and reduce transaminase levels in afected individuals [Diaz et al 2022], which are likely to reduce the risk of liver failure and the need for liver transplantation in the future. \nSplenic involvement. Tose with signifcant organomegaly have hypersplenism with secondary thrombocytopenia. Infarction of the spleen can cause acute abdominal pain. However, ERT has been shown to improve the splenomegaly and thrombocytopenia in afected individuals [Diaz et al 2022]. \nPulmonary involvement is common in afected individuals of all ages [Minai et al 2000, Mendelson et al 2006]. In untreated individuals, clinical impairment ranges from none to oxygen dependence and severe limitations of activity. Most untreated afected individuals have evidence of interstitial lung disease on chest radiographs and thin-section CT. While most individuals have progressive gas exchange abnormalities, the extent of the radiographic fndings may not correlate with impairment of pulmonary function. With ERT, pulmonary function, as measured by percent predicted difusing capacity of the lung for carbon monoxide, signifcantl y improved [Diaz et al 2022]. \nCalcifed pulmonary nodules can also be seen in untreated individuals and were not specifcally studied in those receiving ERT. \nOphthalmologic manifestations. Up to one third of individuals with NPD-B have a macular halo or a cherryred macula. Most have no evidence of progressive neurologic disease; the presence of a macular halo or a cherryred macula is not an absolute predictor of neurodegeneration [McGovern et al 2004b], and there do not appear to be any clinical consequences with respect to visual function. Tis aspect of ASMD was not studied in children who received ERT. \nGrowth.",
      "token_count": 475,
      "sentence_count": 17
    },
    {
      "id": "A_Guide_To_Marfan_Syndrome_and_Related_Disorders_txt_10",
      "contents": " The potential for lung problems should offer a powerful incentive for people with Marfan syndrome to avoid or quit all forms of smoking. \ni. Pectus Deformities \nDepression of the breast bone (pectus excavatum) can reduce the space available for the lungs somewhat. This is usually not a problem unless the person also has severe scoliosis and lordosis of the upper spine. A pectus excavatum also interferes with the mechanics of expanding the lungs. The primary symptom is shortness of breath during exercise. A protrusion of the breast bone (pectus carinatum) has little effect on lung volumes or function. \nii. Pneumothorax \nOne possible effect of a mutation in fibrillin-1 is pneumothorax, in which air escapes the lung into the space between the lung and the inner lining of the chest. The symptoms of this are shortness of breath, a dry cough, and often sudden onset of pleuritic chest pain (pain that gets worse when you take a deep breath). The pain may be confused with an aortic dissection or heart attack, and should always prompt evaluation in an emergency room. A pneumothorax is most common in people who have a \u2018bleb\u2019 or bubble of lung tissue, typically at the top of the lungs. \n\niii. Emphysema \nEmphysema is a condition in which the walls of the tiny air sacs in the lungs are damaged so they cannot push all the used air out of the lungs. Approximately $10{-}15\\%$ of people with Marfan syndrome have emphysema, but it may be underdiagnosed. Symptoms include shortness of breath during activity, frequent bronchitis (often as a result of common colds or viruses settling in the chest) and low blood oxygen. The diagnosis can be confirmed by a chest x-ray, CT scan, pulmonary function test or arterial blood test. \niv. Asthma \nAsthma, which is very common in the general population, is also present in the Marfan community. People with Marfan syndrome who have asthma should see a respiratory specialist who can coordinate care with other specialists because the conventional treatments for asthma\u2014beta-agonists\u2014have the opposite effect of beta-blockers (which are prescribed to many people with Marfan syndrome). \nv. Sleep Apnea \n",
      "token_count": 492,
      "sentence_count": 18
    }
  ],
  "scan_analyses": [
    {
      "scan_type": "Chest Scan",
      "scan_date": "2025-03-24T23:06:13.575979",
      "file_name": "images.jpeg",
      "description": "Chest scan",
      "analysis": "Okay, let\u2019s analyze this chest CT scan. \n\n**Overall Impression:**\n\nThis CT scan demonstrates significant bilateral pulmonary involvement, primarily characterized by diffuse, patchy opacities. The findings suggest an inflammatory or infiltrative process affecting the lungs.\n\n**Detailed Findings:**\n\n1. **Lung Fields:**  The lungs appear quite dense, with a significant amount of shadowing present throughout both lung fields. This is the key finding.\n\n2. **Patchy Opacities:** The most prominent feature is the presence of numerous, scattered, patchy areas of increased density (opacities) within the lung parenchyma. These aren't sharply defined nodules or masses. They appear more as \u201ccloud-like\u201d or \u201cpatchy\u201d infiltrates.\n\n3. **Distribution:** The opacities are bilaterally distributed \u2013 meaning they are present in both lungs.  They seem to be more prominent in the lower lobes, but this isn\u2019t entirely consistent throughout.\n\n4. **Bronchovascular Markings:**  The bronchial and pulmonary vascular structures (bronchovascular markings) are somewhat obscured by the surrounding opacities, making it harder to fully assess their anatomy.\n\n5. **Mediastinum:** The mediastinum (the space between the lungs containing the heart, great vessels, etc.) appears unremarkable.  The heart size appears within normal limits on this single slice.\n\n6. **Pleura:** The pleural surfaces (the linings of the lungs) appear clear, with no evidence of pleural effusion (fluid accumulation) visible on this slice. \n\n7. **Hilar Areas:** The hilar areas (where the bronchi and blood vessels enter the lungs) appear normal.\n\n\n**Possible Diagnoses (Differential Considerations):**\n\nBased on these findings, several possibilities need to be considered. This is not a definitive diagnosis, but a list of potential causes:\n\n*   **Pneumonia:** This is a strong consideration given the diffuse, patchy opacities.  It could be bacterial, viral, or atypical pneumonia.\n*   **Acute Respiratory Distress Syndrome (ARDS):** The diffuse opacities could be indicative of ARDS, a severe form of lung injury often following a significant illness or injury.\n*   **Diffuse Interstitial Lung Disease (ILD):**  This is a broad category of diseases characterized by inflammation and scarring in the lung\u2019s interstitium. The patchy nature of the opacities is consistent with some forms of ILD.\n*   **Pulmonary Edema:**  Although less"
    }
  ],
  "analysis_date": "2025-03-25T09:02:55.747407",
  "created_at": "2025-03-25T09:02:55.747410"
}